Phico Therapeutics is a biotechnology company developing a novel platform technology which it believes could form the basis for a new generation of antibiotics to fight against drug-resistant bacteria. The company’s patented platform utilizes an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPject™ could form the basis for a new generation of antibiotics to overcome antimicrobial resistance.
Bacteriophage product pipeline:
- SASPject PT3.9 – target: Pseudomonas aeruginosa
- SASPject PT4 – target: Klebsiella pneumoniae – for intravenous use
- SASPject PT5 – target: Escherichia coli – for intravenous use
- SASPject PT1.2 – target: Staphylococcus aureus – for intra-nasal use